Vaccines

As argenx prepares its full-year 2025 update, investors are watching if the VYVGART sales boom can fund a pipeline aimed at dominating autoimmune care.

After a major pipeline pivot, Keros Therapeutics faces investors with a new lead drug, a fortified balance sheet, and a high-stakes strategy to prove.

New data on Spyre Therapeutics' SPY003 suggests a twice-yearly shot for IBD is possible, part of a broader strategy to challenge market giants.

The research giant took a massive Q4 loss from asset impairments but points to improving client demand and a strategic overhaul as signs of a turnaround.

A new biotech emerges with massive funding and a next-gen 'shuttle' to deliver safer, more effective Alzheimer's therapies directly to the brain.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Cindy Eckert's TIME100 nod follows a major FDA win for her libido drug, Addyi, but spotlights a decade-long battle over efficacy, safety, and equality.

The largest study of its kind reveals metabolic signatures that predict severe neurotoxicity in CAR T-cell patients, paving the way for safer treatments.

Sanofi promotes Dupixent growth driver Manuela Buxo to lead its crucial Specialty Care unit, ensuring continuity as competition and a new AI focus intensify.

A major patent deal shields Esperion's flagship drugs from generics, securing future revenue but delaying cheaper options for millions of patients.

With demand for freeze-drying surging, OFD adds project management veteran Danielle Grosso to its expanding leadership team to scale operations.

An independent board again backs the safety of BriaCell's metastatic breast cancer therapy in a pivotal Phase 3 trial, boosting hope for a new treatment.

With a bolstered balance sheet and a sharpened focus, Palatin Technologies is advancing two novel obesity drugs into clinical trials for rare genetic disorders.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

Oculis appoints former Cooley partner Katie Kazem as CLO, a strategic move to fortify governance ahead of pivotal data readouts for its late-stage eye drugs.

With no approved nonsurgical options for plantar fibromatosis, Keenova's new study and late-stage trial offer a significant glimmer of hope for sufferers.